SCHEMBL20689783

SCHEMBL20689783

COc1cc(N2CCOCC2)c(N)cc1NC(=O)OC(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.48
ALDH1A1 P00352 6/20 0.46
LMNA P02545 2/20 0.44
RAB9A P51151 1/20 0.44
MAPT P10636 3/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
MAPK1 P28482 2/20 0.44
PKM P14618 1/20 0.44
HTT P42858 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
POLB P06746 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
PRKDC P78527 1/20 0.44
TSHR P16473 1/20 0.43
KDM4E B2RXH2 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19221922 0.87 ABL1 (0.46) ALDH1A1MEN1KMT2AMAPK1L3MBTL1
SCHEMBL29823053 0.87 ABL1 (0.46) ALDH1A1MEN1KMT2AMAPK1L3MBTL1
SCHEMBL20681329 0.86 LMNA (0.47) GAAALDH1A1LMNARAB9AMAPT
SCHEMBL19222007 0.84 PTK6 (0.48) ALDH1A1RAB9AMAPTKDM4E
SCHEMBL26577159 0.83 ALDH1A1 (0.52) GAAALDH1A1LMNAMAPTMEN1
SCHEMBL24891451 0.82 ABL1 (0.39) GAAALDH1A1PRKDC
SCHEMBL20689782 0.82 EGFR (0.52) GAAALDH1A1MAPK1
SCHEMBL30518153 0.80 ALDH1A1 (0.49) GAAALDH1A1LMNARAB9AMAPT
SCHEMBL13832429 0.78 BRPF1 (0.45) ALDH1A1MEN1KMT2AMAPK1L3MBTL1
SCHEMBL7141573 0.78 PRKDC (0.44) GAAALDH1A1LMNAMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3658547-B1 PROCESS FOR PREPARING N-(5-(4-(4-FORMYL-3-PHENYL-1H-PYRAZOL-1-YL)PYRIMIDIN-2-YLAMINO)-4-METHOXY-2-MORPHOLINOPHENYL)ACRYLAMIDE YUHAN CORP (KR) 2023-08-16 EP claimed
US-20230322753-A1 HETEROARYL DERIVATIVE, METHOD FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT VORONOI INC. (KR) 2023-10-12 US disclosed
US-20230322753-A1 HETEROARYL DERIVATIVE, METHOD FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT VORONOI INC. (KR) 2023-10-12 US disclosed
EP-3658547-B1 PROCESS FOR PREPARING N-(5-(4-(4-FORMYL-3-PHENYL-1H-PYRAZOL-1-YL)PYRIMIDIN-2-YLAMINO)-4-METHOXY-2-MORPHOLINOPHENYL)ACRYLAMIDE YUHAN CORP (KR) 2023-08-16 EP disclosed
EP-3658547-B1 PROCESS FOR PREPARING N-(5-(4-(4-FORMYL-3-PHENYL-1H-PYRAZOL-1-YL)PYRIMIDIN-2-YLAMINO)-4-METHOXY-2-MORPHOLINOPHENYL)ACRYLAMIDE YUHAN CORP (KR) 2023-08-16 EP disclosed
CN-116194111-A Heteroaryl derivatives, process for preparing the same, and pharmaceutical compositions containing the same as active ingredient 株式会社沃若诺伊生物 2023-05-30 CN disclosed
WO-2022060196-A1 HETEROARYL DERIVATIVE, METHOD FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT 보로노이바이오 주식회사 2022-03-24 WO disclosed
US-11198684-B2 Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the same YUHAN CORPORATION (KR) 2021-12-14 US disclosed
US-20210155607-A1 INTERMEDIATES USEFUL FOR THE SYNTHESIS OF A SELECTIVE INHIBITOR AGAINST PROTEIN KINASE AND PROCESSES FOR PREPARING THE SAME YUHAN CORPORATION (KR) 2021-05-27 US disclosed
WO-2019022487-A1 INTERMEDIATES USEFUL FOR THE SYNTHESIS OF A SELECTIVE INHIBITOR AGAINST PROTEIN KINASE AND PROCESSES FOR PREPARING THE SAME YUHAN CORPORATION (KR) 2019-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210155607-A1 INTERMEDIATES USEFUL FOR THE SYNTHESIS OF A SELECTIVE INHIBITOR AGAINST PROTEIN KINASE AND PROCESSES FOR PREPARING THE SAME ERBB2, EGFR, MAP3K20 GAA 2923/4885ALDH1A1 3633/4885LMNA 4347/4885
US-11198684-B2 Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the same ERBB2, EGFR, MAP3K20 GAA 2923/4885ALDH1A1 3633/4885LMNA 4347/4885
US-20230322753-A1 HETEROARYL DERIVATIVE, METHOD FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT ERBB4, ERBB2, ERBB3 GAA 1944/4885ALDH1A1 2285/4885LMNA 4716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.